PRESENTATION

Q4 2025 — Results presentation

Q4 2025PDF · 33 pages3.9 MB


-- 1 of 33 --

th
January 21, 2026

-- 2 of 33 --

Cautionary note on Forward-looking statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to
applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing
difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government
action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased
scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent
Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent
Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at 	www.sec.gov, 	www.jnj.com, 	www.investor.jnj.com
or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information or future events or developments.
Cautionary note on Non-GAAP financial measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website.
3

-- 3 of 33 --

REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology; JNJ-2113 was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize
for a broad range of indications
Immunology
INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.	Neuroscience
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV
Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in part with
federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
(BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) at the U.S.
Department of Health and Human Services (HHS)
Infectious Diseases
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Cardiovascular/
Metabolism/Other
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration
with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals,
Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited;
AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from
Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs;
ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Oncology
UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan	Pulmonary Hypertension
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® 	is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Global Public Health
Strategic partnerships, collaborations
& licensing arrangements
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:
4

-- 4 of 33 --

CEO Remarks
Sales performance and earnings review
Cash position and guidance update
Q&A
Agenda
5
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech
1
2
3
4

-- 5 of 33 --

Joaquin Duato
Chairman and Chief Executive Officer

-- 6 of 33 --

2025 was a
catapult year full-year operational sales growth
platforms with at least $1 billion
annual revenue	28
SHOCKWAVE
CARVYKTI
each surpass $1 billion in annual
sales for first time
5.3%1,2
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (620) basis point headwind from STELARA
7

-- 7 of 33 --

Innovative Medicine
1,2
full-year
operational
sales growth
2025-at-a-glance
~$60
billion annual
sales
13
brands growing
double digits
51
approvals and 	32
filings across
major markets3
17
key studies with
positive readouts
11
new phase 3
programs
initiated
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes an approximate (1,040) basis point headwind from STELARA
3 	Includes the U.S., EU, Japan, and China
8

-- 8 of 33 --

Innovative Medicine
Oncology 	Neuroscience	Immunology
9

-- 9 of 33 --

MedTech
1
full-year
operational
sales growth
2025-at-a-glance
~$34
billion annual sales
15
launches in major markets2
40+
regulatory approvals
in major markets2
60+
active clinical trials
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Includes the U.S. and EU
10

-- 10 of 33 --

MedTech
Addressing one of the largest unmet
needs in healthcare
Advancing the science of surgery
and pioneering what's next
Developing transformational innovations
to improve the health of patients’ eyes
Cardiovascular 	Surgery 	Vision
MedTech Innovation: 	MedTech Innovation: 	MedTech Innovation:
VARIPULSE 	Platform 	Dual Energy THERMOCOOL
SMARTTOUCH 	SF Catheter
Shockwave Intravascular
Lithotripsy System
OMNYPULSE
Catheter
OTTAVA
Robotic
Surgical
System
ETHICON 	4000
Surgical Stapler
ACUVUE® OASYS 1-Day Family
TECNIS Odyssey 	TECNIS PureSee
Impella® Heart
Pump Technology
MONARCH
Platform
11

-- 11 of 33 --

Note: related to sales; excludes the impact of translational currency
12

-- 12 of 33 --

Darren Snellgrove
Vice President,
Investor Relations

-- 13 of 33 --

% Change
Q4 2024	Q4 2025	Regional sales results 	Operational1
Reported
7.5%	7.5%	$13.2	$14.2	U.S.
5.2	13.8	4.9	5.6	Europe
11.0	12.0	1.1	1.3
Western Hemisphere
(ex U.S.)
7.2	7.4	3.3	3.5	Asia-Pacific, Africa
6.6	11.3	9.3	10.4	International
7.1%	9.1%	$22.5	$24.6	Worldwide (WW)
Dollars in billions
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
4th Quarter 2025 sales
14

-- 14 of 33 --

$24.6 $22.5
$6.0
$4.9
20.6%; 	15.2%1
$2.46
$2.043
Dollars in billions, except EPS
Reported %; 	Operational %1
Sales
Adjusted earnings2 	Adjusted EPS2
9.1%; 	7.1%1
GAAP earnings
$5.1
$3.4
21.5%
Q4 2025 	Q4 2024
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Includes $(0.22) due to acquired IPR&D charges related to V-wave acquisition
4th Quarter 2025 financial highlights
GAAP EPS
15
Q4 2025 	Q4 2024 	Q4 2025 	Q4 2024
Q4 2025 	Q4 2024 	Q4 2025 	Q4 2024
$2.10
$1.413
49.1% 	48.9%

-- 15 of 33 --

% Change
2024	2025	Regional sales results 	Operational1
Reported
6.9%	6.9%	$50.3	$53.8	U.S.
2.4	6.5	20.2	21.5	Europe
8.4	3.4	4.7	4.9
Western Hemisphere
(ex U.S.)
3.1	3.2	13.6	14.0	Asia-Pacific, Africa
3.4	5.0	38.5	40.4	International
5.3%	6.0%	$88.8	$94.2	Worldwide (WW)
Dollars in billions
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
Full-year 2025 sales
16

-- 16 of 33 --

$26.2
$24.2
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Includes $(0.67) due to acquired IPR&D charges on various transactions throughout the year
8.1%; 	6.0%1
$10.79 $9.983
Dollars in billions, except EPS
Reported %; 	Operational %1
Sales
Adjusted earnings2 	Adjusted EPS2
6.0%; 	5.3%1 90.6%
$26.8
$14.1
8.1%
90.5%
$11.03
$5.793
2025 	2024 	2025 	2024 	2025 	2024
$94.2 $88.8
2025 	2024 	2025 	2024
Full-year 2025 financial highlights
GAAP EPS
17
GAAP earnings

-- 17 of 33 --

Immunology
$3,860	Infectious Diseases
$807
Neuroscience
$2,115
Oncology
$6,861
CVM/Other
$936
PH
$1,184
■ 	Reported growth 	■ 	Operational growth1
$15,763
10.0%, 	7.9%
WW sales $MM
Key drivers of operational performance1
• 	DARZALEX increase primarily driven by continued strong share gains as well as inventory
dynamics and market growth
• 	ERLEADA growth driven by market growth and continued share gains, partially offset by the
impact of Part D redesign
• 	CARVYKTI increase driven by continued share gains and site expansion
• 	TECVAYLI and TALVEY growth driven by continued share gains
• 	RYBREVANT/LAZCLUZE increase driven by ongoing launch and share gains
• 	Growth partially offset by ZYTIGA loss of exclusivity and IMBRUVICA due to the impact of
Part D redesign and competitive pressures
Oncology
• 	TREMFYA increase due to share gains and market growth
• 	SIMPONI/SIMPONI ARIA growth driven primarily by market growth, partially offset by share
decline
• 	REMICADE increase due to favorable patient mix and market growth, partially offset by
biosimilar competition
• 	STELARA decline driven by the impact of biosimilar competition and Part D redesign
Immunology
• 	SPRAVATO growth driven by continued increased physician and patient demand
• 	CAPLYTA acquired April 2, 2025
• 	INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA decline primarily driven by the
impact of Part D redesign
Neuroscience
• 	UPTRAVI increase driven by inventory dynamics and market growth, partially offset by the
impact of Part D redesign
• 	OPSUMIT/OPSYNVI growth driven by share gains, market growth, and favorable patient mix,
partially offset by the impact of Part D redesign
Pulmonary
Hypertension (PH)
• 	Declines across the portfolio partially offset by EDURANT growth	Infectious Diseases
• 	XARELTO growth driven by the impact of Part D redesign and market growth, partially offset
by continued share loss
Cardiovascular /
Metabolism / Other
(CVM/Other)
Adjusted operational sales2: WW: 6.2%, U.S. 5.1%, Int’l 8.0%
Innovative Medicine highlights – 4th quarter 2025
WW 10.0%, U.S. 7.9%, Int’l 13.4%	Reported:
WW 7.9%, U.S. 7.9%, Int’l 7.9%	Operational1:
(2.2)%, 	(2.9)%
8.4%, 	7.4%
24.8%, 	21.9%
4.3%, 	(0.4)%
(8.9)%, 	(10.3)%
Strong operational growth1 of 7.9% driven primarily by Oncology and Neuroscience
19.1%, 	17.9%
18
Stelara impacted results1 	by ~(1,110) basis points
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded

-- 18 of 33 --

Key drivers of operational performance1
• 	Electrophysiology: Growth driven by procedure growth, commercial execution, and new product
performance (VARIPULSE, TRUPULSE, NUVISION), partially offset by competitive pressures in PFA
• 	Abiomed: Double digit growth driven by continued strong adoption of Impella 5.5 and Impella CP
• 	Shockwave: 	Double digit growth driven by Coronary and Peripheral portfolios and new product
launches (JAVELIN & E8)
Cardiovascular
All platforms impacted by revenue disruption from the previously announced Orthopaedics
transformation, which is now substantially complete:
• 	Hips: 	Increase driven by new product launches (EMPHASYS)
• 	Trauma: 	Growth driven by recently launched products (VOLT) and commercial execution, partially
offset by trade inventory dynamics and volume-based procurement (VBP) in China
• 	Knees: 	Increase driven by commercial execution and strength of the ATTUNE portfolio, partially
offset by trade inventory dynamics and VBP in China
• 	Spine, Sports & Other: 	Growth driven by spine innovations (TriAltis) and commercial execution,
partially offset by competitive pressures and price pressures in the U.S. Early Interventional segment
• 	Spine: 	~ +3% WW, ~ +5% U.S., ~ -1% Int’l
Orthopaedics
• 	Advanced:
• 	Biosurgery: 	~ +5% growth driven by continued strength of the portfolio and commercial
execution, partially offset by VBP in China
• 	Endocutters: 	~ -3% due to VBP in China and competitive pressures
• 	Energy: 	~ Flat due to competitive pressures, Harmonic market decline in the U.S., and VBP in
China, offset by OUS growth
• 	General: 	Growth primarily due to technology penetration and upgrades within our differentiated
Wound Closure portfolio (Barbed & PLUS Sutures) coupled with commercial execution
Surgery
• 	Contact Lenses/Other: 	Increase driven by market growth, strong performance of the ACUVUE
OASYS 1-Day family, and continued strategic price actions
• 	Surgical: 	Growth driven by strength of recent product innovations (TECNIS PureSee, TECNIS
Odyssey, TECNIS Eyhance), robust demand for premium IOLs, and strong commercial execution
Vision
Adjusted operational sales2: WW 5.9%, U.S. 6.7%, Int’l 5.1%
Orthopaedics
$2,438
Surgery
$2,644
Vision
$1,420
Cardiovascular
$2,299
■ 	Reported growth 	■ 	Operational growth1
$8,801
7.5%, 	5.8%
WW sales $MM
Strong operational growth1 of 5.8% due to commercial execution and innovation
WW 7.5%, U.S. 6.6%, Int’l 8.5%	Reported:
WW 5.8%, U.S. 6.6%, Int’l 4.9%	Operational1:
11.5%, 	10.1%
8.9%, 	6.8%
5.3%, 	3.5%
5.5%, 	3.7%
MedTech highlights – 4th quarter 2025
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded 	19

-- 19 of 33 --

%
Increase
(Decrease)
2024	2025
% to Sales	Amount	% to Sales	Amount
9.1	100.0	$22,520	100.0	$24,564	Sales to customers
11.8	31.6	7,128	32.4	7,968	Cost of products sold
7.8	68.4	15,392	67.6	16,596	Gross Profit
4.6	28.6	6,453	27.5	6,753	Selling, marketing and administrative expenses
(19.7)	23.5	5,298	17.3	4,252	Research and development expense
0.1	17	0.3	81	In-process research and development impairments
(0.6)	(144)	(0.1)	(23)	Interest (income) expense, net
(0.7)	(161)	2.0	483	Other (income) expense, net
0.2	42	0.4	84	Restructuring
27.8	17.3	3,887	20.2	4,966	Earnings before provision for taxes on income
(132.9)	2.1	456	(0.6)	(150)	(Benefit from)/Provision for taxes on income
49.1	15.2	$3,431	20.8	$5,116	Net Earnings
-
48.9	$1.41	$2.10	Net earnings per share (Diluted)
2,427.1	2,439.0	Average shares outstanding (Diluted)
11.7%	(3.0)%	Effective tax rate
.
Adjusted earnings before provision for taxes and net earnings1
30.0	24.1	$5,421	28.7	$7,046	Earnings before provision for taxes on income
21.5	22.0	$4,946	24.5	$6,009	Net earnings
20.6	$2.04	$2.46	Net earnings per share (Diluted)
8.8%	14.7%	Effective tax rate
1 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
(Unaudited; Dollar and shares in millions except per share figures)
20
4th Quarter 2025
Condensed consolidated statement of earnings

-- 20 of 33 --

%
Increase
(Decrease)
2024	2025
Innovative Medicine % to Sales	Amount	% to Sales	Amount
10.0	100.0	$14,332	100.0	$15,763	Sales to customers
15.3	19.7	2,829	20.7	3,261	Cost of products sold
8.7	80.3	$11,503	79.3	$12,502	Gross Profit
4.3	23.1	3,312	21.9	3,456	Selling, marketing and administrative expenses
(6.1)	25.8	3,692	22.0	3,466	Research and development expense
(1.1)	(158)	(0.9)	(135)	Other segment items 	1
22.7	32.5	$4,657	36.3	$5,715	Adjusted segment income before tax 	2
(Unaudited; Dollar in millions)
Adjusted earnings before provision for taxes on income by segment
21
%
Increase
(Decrease)
2024	2025
MedTech % to Sales	Amount	% to Sales	Amount
7.5	100.0	$8,188	100.0	$8,801	Sales to customers
17.3	35.8	2,928	39.0	3,435	Cost of products sold
2.0	64.2	$5,260	61.0	$5,366	Gross Profit
7.2	34.6	2,832	34.5	3,035	Selling, marketing and administrative expenses
(50.1)	19.2	1,575	8.9	786	Research and development expense 	3
(0.4)	(33)	0.2	10	Other segment items 	1
73.3	10.8	$886	17.4	$1,535	Adjusted segment income before tax 	2
%
Increase
(Decrease)
2024	2025
Enterprise % to Sales	Amount	% to Sales	Amount
30.0	24.1	$5,421	28.7	$7,046	Adjusted income before tax 	2
4th Quarter 2025
1 	Other segment items for each reportable segment include charges related to other income and expenses
2 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Includes acquired IPR&D for V-Wave in Q4 2024, totaling $540
Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the 	company's website

-- 21 of 33 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 22 of 33 --

Capital allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
Higher
priority
Lower
priority
Investment in M&A
Q4 2025	Dollars in billions
~$20
Cash and marketable
securities
~($48)	Debt
~($28)	Net debt
~$20	Free cash flow1,2
Full-year 2025:
$14.7B 	invested in R&D
$12.4B 	in dividends paid
to shareholders
Note: Values may be rounded
1 	Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment
2 	Estimated as of January 21, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
Note: Values may be rounded
Capital allocation strategy
23

-- 23 of 33 --

Operational2 sales guidance of 6.2% and adjusted operational EPS2,4 at 5.5% (midpoints)
Comments	January 2026
Midpoint of 5.9%	5.4% - 6.4%	Adjusted operational sales1,2
Midpoint of $100.0B or 6.2%
$99.5B - $100.5B
5.7% - 6.7%
Operational sales2
Midpoint of $100.5B or 6.7%
FX impact of $0.5B or 0.5%
$100.0B - $101.0B
6.2% - 7.2%
Estimated reported sales 	3
Net impact of operating efficiencies	Increase of at least 50 bps
Adjusted pre-tax
operating margin4,5
Relatively flat to 2025 levels	$1.0 - $1.2 billion	Net other income4
Higher average debt levels	$300 - $400 million	Net interest expense / (income)
Change in income mix	17.5% - 18.5%	Effective tax rate4
Midpoint of $11.38 or 5.5%
$11.28 - $11.48
4.5% - 6.5%
Adjusted EPS (operational)2,4
Midpoint of $11.53 or 6.9%
FX impact of $0.15 or 1.4%
$11.43 - $11.63
5.9% - 7.9%
Adjusted EPS (reported)3,4
Consistent with Q4 2025 shares outstanding	~2,440 million	Average shares outstanding6
2026 P&L guidance
1 	Non-GAAP measure; excludes acquisitions and divestitures 	4 	Non-GAAP measure; excludes intangible amortization expense and special items
2 	Non-GAAP measure; excludes the impact of translational currency 	5 	Sales less: COGS, SM&A and R&D expenses
3 	Euro Average Rate: January 2026 = $1.17; Euro Spot Rate: January 2026 = $1.17 	6 	Full-year 2026 projected average shares outstanding (diluted)
Note: Values may be rounded 	24

-- 24 of 33 --

Innovative
Medicine
• 	Expect more pronounced impact from newly launched products as the year progresses
• 	Regarding STELARA, HUMIRA erosion curve remains the best proxy2
• 	Anticipate generic competition for OPSUMIT (second half in U.S.) and SIMPONI (first half in EU; potentially second half in U.S.)
• 	Expect impact of voluntary agreement with the U.S. government to be evenly distributed throughout the year
• 	Expect continued acceleration of newly launched products as the year progresses with normalized seasonality
• 	Surgery transformation topline sales headwind expected to accelerate throughout the year
• 	Anticipate additional rounds of VBP in China throughout the year
• 	The impact of tariffs assumed to be consistent throughout the year
2026 Phasing Considerations
MedTech
• 	Expect heavy investment in Q1 2026 compared to the rest of the year
• 	One-time items impacting EPS last year:
• 	Impact of Stelara erosion in Q1 2025 was less pronounced
• 	Intra-Cellular benefit laps in Q2
• 	Impact of tariffs laps in Q4
• 	Anticipate higher earnings per share growth in the second half of the year compared to the first half
P&L
25
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	STELARA Year 2 erosion curve assumes best proxy with HUMIRA Year 3 erosion curve
Anticipate fairly consistent operational1 sales growth in the first and second half; 53rd week impacts the second half

-- 25 of 33 --

Innovative Medicine
Anticipated 2026 milestones1 driving long-term value creation
MedTech
26
ICOTYDE in PsO
TECVAYLI + DARZALEX in RRMM
TREMFYA in PsA SD
TECVAYLI in RRMM
INLEXZO in HR NMIBC
nipocalimab in WAIHA and SLE
CAPLYTA in bipolar mania
JNJ-4804
ERLEADA in LPC & HRPC
OTTAVA
ETHIZIA
STSF Dual Energy Catheter
C2 Aero Catheters
TECNIS PureSee IOL
ATTUNE Hinge
VOLT
MONARCH Urology
1 	List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches
PsO: Psoriasis; RRMM: Relapsed/refractory multiple myeloma; PsA SD: Psoriatic arthritis structural damage; HR NMIBC: High-risk non-muscle invasive bladder cancer; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; LPC: Localized prostate cancer; HRPC: High-risk
prostate cancer; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens

-- 26 of 33 --

Q&A
John Reed
Executive Vice President,
Innovative Medicine, R&D
Joaquin Duato
Chairman and
Chief Executive Officer
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Darren Snellgrove
Vice President,
Investor Relations
Jennifer Taubert
Executive Vice President,
Worldwide Chairman,
Innovative Medicine
Tim Schmid
Executive Vice President,
Worldwide Chairman,
MedTech

-- 27 of 33 --

Slide footer goes here if required 	28

-- 28 of 33 --

Immunology
$15,728	Infectious Diseases
$3,241
Neuroscience
$7,837
Oncology
$25,380 CVM/Other
$3,778
PH
$4,437
■ 	Reported growth 	■ 	Operational growth1
$60,401
6.0%, 	5.3%
WW sales $MM
WW 6.0%, U.S. 7.0%, Int’l 4.6%	Reported:
WW 5.3%, U.S. 7.0%, Int’l 2.9%	Operational1:
Orthopaedics
$9,258
Surgery
$10,137
Vision
$5,468
Cardiovascular
$8,928
■ 	Reported growth 	■ 	Operational growth1
$33,792
6.1%, 	5.4%
WW sales $MM
Innovative Medicine and MedTech FY 2025 Sales
6.1%, 	6.0%
3.6%, 	3.2%
22.1%, 	20.9%
(4.6)%, 	(6.5)%
(11.8)%, 	(12.0)%
Innovative Medicine
10.1%, 	9.9%
29
1 	Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
2 	Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the 	company's website
Note: Values may be rounded
Adjusted operational sales2: WW: 4.1%, U.S. 4.9%, Int’l 3.0%
MedTech
Adjusted operational sales2: WW 4.3%, U.S. 4.8%, Int’l 3.8%
15.8%, 	15.2%
6.3%, 	5.3%
1.1%, 	0.3%
3.0%, 	2.5%
Strong full-year 2025 operational sales growth1 across Innovative Medicine and MedTech
WW 6.1%, U.S. 6.6%, Int’l 5.5%	Reported:
WW 5.4%, U.S. 6.6%, Int’l 4.1%	Operational1:

-- 29 of 33 --

%
Increase
(Decrease)
2024	2025
% to Sales	Amount	% to Sales	Amount
6.0	100.0	$88,821	100.0	$94,193	Sales to customers
10.1	30.9	27,471	32.1	30,256	Cost of products sold
4.2	69.1	61,350	67.9	63,937	Gross Profit
3.5	25.7	22,869	25.1	23,676	Selling, marketing and administrative expenses
(14.9)	19.4	17,232	15.6	14,665	Research and development expense
0.2	211	0.1	81	In-process research and development impairments
(0.6)	(577)	(0.1)	(85)	Interest (income) expense, net
5.3	4,694	(7.6)	(7,209)	Other (income) expense, net
0.3	234	0.2	228	Restructuring
95.2	18.8	16,687	34.6	32,581	Earnings before provision for taxes on income
120.4	3.0	2,621	6.1	5,777	Provision for taxes on income
90.6	15.8	$14,066	28.5	$26,804	Net Earnings
-
90.5	$5.79	$11.03	Net earnings per share (Diluted)
2,429.4	2,429.4	Average shares outstanding (Diluted)
15.7%	17.7%	Effective tax rate
.
Adjusted earnings before provision for taxes and net earnings1
9.3	32.6	$28,979	33.6	$31,681	Earnings before provision for taxes on income
8.1	27.3	$24,242	27.8	$26,215	Net earnings
8.1	$9.98	$10.79	Net earnings per share (Diluted)
16.3%	17.3%	Effective tax rate
1 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website
(Unaudited; Dollar and shares in millions except per share figures)
30
Full-year 2025
Condensed consolidated statement of earnings

-- 30 of 33 --

%
Increase
(Decrease)
2024	2025
Innovative Medicine % to Sales	Amount	% to Sales	Amount
6.0	100.0	$56,964	100.0	$60,401	Sales to customers
14.7	19.8	11,256	21.4	12,905	Cost of products sold
3.9	80.2	$45,708	78.6	$47,496	Gross Profit
4.3	19.1	10,906	18.8	11,375	Selling, marketing and administrative expenses
(12.4)	23.7	13,504	19.6	11,827	Research and development expense 	1
(2.0)	(1,154)	(1.2)	(706)	Other segment items 	2
11.3	39.4	$22,452	41.4	$25,000	Adjusted segment income before tax 	3
(Unaudited; Dollar in millions)
Adjusted earnings before provision for taxes on income by segment
31
%
Increase
(Decrease)
2024	2025
MedTech % to Sales	Amount	% to Sales	Amount
6.1	100.0	$31,857	100.0	$33,792	Sales to customers
12.3	34.9	11,122	37.0	12,491	Cost of products sold
2.7	65.1	$20,735	63.0	$21,301	Gross Profit
5.2	33.9	10,796	33.6	11,354	Selling, marketing and administrative expenses
(18.6)	11.1	3,530	8.5	2,875	Research and development expense 	4
(1.5)	(487)	(0.6)	(210)	Other segment items 	2
5.6	21.6	$6,896	21.5	$7,282	Adjusted segment income before tax 	3
%
Increase
(Decrease)
2024	2025
Enterprise % to Sales	Amount	% to Sales	Amount
9.3	32.6	$28,979	33.6	$31,681	Adjusted income before tax 	3
Full-year 2025
1 	Includes acquired IPR&D for the global rights to the NM26 bispecific antibody in Q3 2024, totaling $1,250 	4 	Includes acquired IPR&D for V-Wave in Q4 2024, totaling $540
2 	Other segment items for each reportable segment include charges related to other income and expenses 	Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the 	company's website
3 	Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the 	company's website

-- 31 of 33 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
P 	US 	SIMPONI (golimumab) 	P 	US 	IMAAVY (nipocalimab 	) 	US 	nipocalimab 	P 	US
INLEXZO (gemcitabine intravesical
delivery system) 	P 	AKEEGA (niraparib/abiraterone) 	P
INLEXZO (gemcitabine delivery
intravesical system)
P 	EU 	Pediatric Ulcerative Colitis
(PURSUIT 2)
P 	EU 	Generalized Myasthenia Gravis
(Vivacity MG3)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
STELARA (ustekinumab) 	P 	US 	SPRAVATO (esketamine) 	TREMFYA (guselkumab) 	P 	US 	AKEEGA (niraparib/abiraterone) 	P 	RYBREVANT / LAZCLUZE 	P 	RYBREVANT (amivantamab)
P 	EU 	Pediatric Crohn's Disease (UNITI
JR)
Treatment Resistant Depression
monotherapy (TRD4005)
P 	EU 	Ulcerative Colitis Subcutaneous
Induction (ASTRO)
P 	EU 	M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Non Small Cell Lung Cancer (MARIPOSA
Final OS)
Head and Neck Cancer (ORIGAMI-4)
P 	US 	TREMFYA (guselkumab) 	P 	US 	CAPLYTA (lumateperone) 	P 	US 	TREMFYA (guselkumab) 	P 	US 	TECVAYLI (teclistamab) 	P 	TREMFYA (guselkumab) 	P 	TALVEY + TECVAYLI
P 	EU 	Ulcerative Colitis Subcutaneous
Induction (ASTRO)
Adjunctive Treatment for Major
Depressive Disorder
Psoriatic Arthritis Structural
Damage (APEX)
0 	Multiple Myeloma 1-3PLs (MajesTEC-
3)
Ulcerative Colitis Subcutaneous Induction
(ASTRO)
Multiple Myeloma
Relapsed/Refractory (RedirecTT-1)
P 	US 	TREMFYA (guselkumab) 	P 	US 	DARZALEX (daratumumab) 	TREMFYA (guselkumab) 	P 	TREMFYA (guselkumab) 	P 	JNJ-4496
P 	EU 	Crohn's Disease Subcutaneous
Induction (GRAVITI)
P 	EU 	Smoldering Multiple Myeloma
(AQUILA)
P 	EU 	Pediatric Psoriasis
(PROTOSTAR)
Psoriatic Arthritis Structural Damage
(APEX)
Hematological Malignancies
(LYM1001)
P 	US 	TREMFYA (guselkumab) 	US 	DARZALEX (daratumumab) 	P 	US 	STELARA (ustekinumab) 	P 	TREMFYA (guselkumab) 	P 	JNJ-5322
Pediatric Psoriasis
(PROTOSTAR)
P 	EU 	Frontline multiple myeloma
transplant ineligible (CEPHEUS)
P 	EU 	Pediatric Ulcerative Colitis
(UNIFI JR)
Pediatric Psoriasis (PROTOSTAR) 	Multiple Myeloma (MMY1001)
P 	US 	TREMFYA (guselkumab) 	P 	US
INLEXZO (gemcitabine intravesical
delivery system) 	P 	US 	STELARA (ustekinumab) 	P 	icotrokinra 	P 	RYBREVANT (amivantamab)
Pediatric Juvenile Psoriatic
Arthritis
Non Muscle Invasive Bladder Cancer
(SunRISe-1)
Pediatric Crohn's Disease (UNITI
JR)
Psoriasis (ICONIC-LEAD) 	Colorectal Cancer (ORIGAMI-1 right-
sided)
P 	US 	TREMFYA (guselkumab) 	P 	US 	RYBREVANT (amivantamab) 	P 	US 	icotrokinra 	P 	icotrokinra 	P 	JNJ-8343
P 	EU 	Crohn's Disease (GALAXI) 	P 	EU 	Subcutaneous (PALOMA-3) 	P 	EU 	Psoriasis (ICONIC) 	Psoriasis (ICONIC-TOTAL) 	Prostate Cancer (PCR1001)
TREMFYA (guselkumab) 	IMBRUVICA (ibrutinib) 	P 	icotrokinra 	JNJ-4804 Co-antibody Therapy
P 	EU 	Ulcerative Colitis (QUASAR) 	P 	EU 	Frontline MCL (Triangle) 	Psoriasis (ICONIC-Advance1/2) 	Psoriatic Arthritis (AFFINITY)
P 	US 	IMAAVY (nipocalimab 	) 	P 	aticaprant 	P 	icotrokinra
Generalized Myasthenia Gravis
Pediatrics (VIBRANCE MG)
Adjunctive Treatment for Major Depressive
Disorder with Anhedonia (Ventura 1)
Ulcerative Colitis (ANTHEM)
P 	US 	AKEEGA (niraparib/abiraterone) 	P 	RPGR Gene Therapy
M1 Metastatic Castration-Sensitive
Prostate Cancer (AMPLITUDE)
Retinitis Pigmentosa (LUMEOS)
P 	TECVAYLI (teclistamab)
Multiple Myeloma 1-3PLs (MajesTEC-3)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2025*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and
does not guarantee continued investment. This information is as of January 26, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
= 	Achieved
1 	In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not
guarantee continued investments. This information is as of January 21, 2026 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.

-- 32 of 33 --

POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA PRESENTATIONS¹
Phase III 	Phase I/ II
US 	TREMFYA (guselkumab) 	US 	nipocalimab 	US 	ERLEADA (apalutamide) 	icotrokinra 	ERLEADA (apalutamide) 	JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis Structural
Damage (APEX)
Warm Autoimmune Hemolytic
Anemia (ENERGY)
EU 	Localized Prostate Cancer
(ATLAS)
Psoriasis (ICONIC-ADVANCE
1&2 Update)
Localized Prostate Cancer (ATLAS) 	Ulcerative Colitis (DUET-UC)
US 	icotrokinra 	US 	CAPLYTA (lumateperone) 	US 	ERLEADA (apalutamide) 	icotrokinra 	ERLEADA (apalutamide) 	JNJ-4804 Co-antibody Therapy
EU 	Psoriasis (ICONIC) 	Bipolar Mania 	EU 	High Risk Prostate Cancer
(PROTEUS)
Psoriasis (ICONIC-ASCEND) 	High Risk Prostate Cancer
(PROTEUS)
Crohn's Disease (DUET-CD)
AKEEGA (niraparib/abiraterone) 	US 	bleximenib 	icotrokinra 	TALVEY (talquetamab) 	JNJ-4804 Co-antibody Therapy
EU 	M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)
Psoriatic Arthritis (ICONIC-PsA) 	Relapsed Refractory Multiple
Myeloma A-CD38 Naïve
(MonumenTAL-3)
Psoriatic Arthritis (AFFINITY)
US 	DARZALEX (daratumumab) 	US 	TALVEY (talquetamab) 	icotrokinra 	TECVAYLI (teclistamab) 	nipocalimab
Frontline multiple myeloma
transplant ineligible (CEPHEUS)
EU 	Relapsed Refractory Multiple
Myeloma A-CD38 Naïve
(MonumenTAL-3)
Psoriasis (ICONIC-TOTAL
Update)
Relapsed Refractory Multiple
Myeloma CD38 exposed (MajesTEC-
9)
Systemic Lupus Erythematosus
(JASMINE)
US 	TECVAYLI (teclistamab) 	US 	TECVAYLI (teclistamab) 	CAPLYTA (lumateperone)
INLEXZO (gemcitabine intravesical
delivery system) 	bleximenib
EU 	Multiple Myeloma 1-3PLs
(MajesTEC-3)
EU 	Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)
Bipolar Mania (ITI-007-452) 	High Risk Non Muscle Invasive
Bladder Cancer BCG Experienced
(SunRISe-5)
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)
TECVAYLI (teclistamab) 	JNJ-1887 	sCD59
P 	EU 	Multiple Myeloma 1-3PLs
(MajesTEC-3)
Geographic Atrophy (PARASOL)
US
INLEXZO (gemcitabine
intravesical delivery system)
EU 	High Risk Non Muscle Invasive
Bladder Cancer BCG
Experienced (SunRISe-5)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2026*
1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs
and assets and does not guarantee continued investment. This information is as of "&Date&" to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.
= 	Achieved
1 	In order to be on key events clinical presentation, data must be presented at a major medical meeting.
*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not
guarantee continued investments. This information is as of January 21, 2026 to the best of the Company’s knowledge. Johnson & Johnson assumes no obligation to update this information.

-- 33 of 33 --